Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 117 people in the neratinib group and 116 people in the lapatinib plus capecitabine (a combination treatment) group — 233 participants in total. The trial was studying women with a type of advanced breast cancer that tests positive for a protein called ErbB2 (also known as HER2). The main thing being measured was "progression-free survival" — that is, how many months passed before the cancer started growing again or a participant died. Several other things were also tracked, including how long participants lived overall, how many showed a measurable shrinkage in their tumours, and how often the cancer spread to the brain. The reported data shows that for the primary measure, progression-free survival, the neratinib group had a median (middle value) of 4.53 months, compared with 6.83 months in the lapatinib plus capecitabine group. For overall survival — the time from joining the trial until death from any cause — the reported median was 19.74 months for neratinib and 23.62 months for the combination group. When it came to the proportion of participants whose tumours shrank to a meaningful degree (called the objective response rate), the reported figures were 29.1% for neratinib and 40.5% for the combination. The clinical benefit rate — which also counted people whose disease stayed stable for at least 24 weeks — was reported as 44.4% for neratinib and 63.8% for the combination. Among those who did respond, the reported duration of that response was 12.48 months for neratinib and 7.98 months for the combination. Finally, the proportion of participants who had the cancer progress specifically in the brain was reported as 9.4% in the neratinib group and 12.9% in the combination group. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Breast Cancer Trial, Completed
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- You have been diagnosed with advanced or late-stage breast cancer (Stage IIIB, IIIC, or IV) that tests positive for a protein called HER2 (also written as erbB2)
- You have previously been treated with a drug called Herceptin (trastuzumab) and a type of chemotherapy called a taxane
- Your heart and kidneys are working well enough to take part (confirm with trial site)
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- You have been treated with Herceptin (trastuzumab) as part of more than 2 different treatment plans, or you have previously taken Xeloda (capecitabine) and/or Tykerb (lapatinib)
- Your bones are the only part of your body where the cancer has spread
- Your cancer has spread to the brain or spinal cord and is currently active — those whose brain/spinal cord disease is stable and who are no longer taking anti-seizure medications or steroids may still be considered (confirm with trial site)
- You have a significant digestive or stomach condition where diarrhoea is a major problem
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial was run
These are the locations recorded on the registry, including 4 in Australia. They are a historical record: this trial is not enrolling, so they are not places you can join it.
Primary endpoints
Progression Free Survival
Other options
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.